MES of the Future

Manufacturing Execution Systems (MES) of the future brings together both biomanufacturers and supply partners to define future user requirements and accelerate solutions for an MES of the future that works in sync with the biomanufacturing industry needs and growth.

Industry needs are not clearly defined and understood

Current MES systems are expensive, slow to implement, and lack the flexibility/agility/openness to be efficiently updated and implemented. The experience of many biomanufacturing companies is that integrating an MES product into a production landscape involves defining, developing, and implementing expensive, custom-built interfaces to effectively extract and combine data. MESs have evolved from basic data collection tools into sophisticated systems that drive operational excellence. However, their full potential is only unlocked when integrated seamlessly with other software solutions. Understanding your digital plant maturity across the board is key to making the right decisions. New requirements and technologies are frequently emerging meaning that current approaches quickly become outdated.

Data management is becoming increasingly difficult to navigate through as each supplier adopts their own unique approach in configuring and managing data at each stage of the manufacturing process. The absence of a standardized framework for handling priority data poses challenges for manufacturers.

The definition of an MES is changing or overlapping with CMMS, LIMS, PLM, etc, clear interface roles and responsibilities are not readily available to the industry and businesses are making decisions in silo. “MES” or “execution needs” are siloed across the drug lifecycle. Tech transfer of execution definitions/recipes from pre-clinical to clinical to commercial have a direct impact on MES, yet this is not fully understood and considered.

Existing supply partners do not fully understand the biomanufacturing industry needs as they are not easily contextualised and understood or built into product roadmaps, which exacerbates the problem long term.

Manufacturers and supply partners working together

Following the publication of the MES Manifesto, the goal of the workstream is now to provide a vehicle for manufacturers and supply partners to work together to develop potential solutions and a common industry-wide view that will accelerate change and overcome existing challenges and limitations. The MES of the Future program is a way to collaborate and share knowledge with the biomanufacturers and MES supply partners. It improves the understanding of the value proposition, challenges, and best practice for MES integration in the biopharmaceutical industry.

The team are empowered together to accelerate progress in defining the MES of the Future, including:

  • The optimization of production costs and manufacturing efficiency by improving best practices, streamlining processes, and enhancing seamless data flows between MES and other systems
  • Increased speed to market through dynamic and agile integrations
  • Understanding what level of digital plant maturity is right for your site in regards to MES
  • Practical guidance and clear recommendations on how to successfully integrate MES in a given IT ecosystem, which can enable the prevention of common mistakes, optimizing the implementation process
  • Increase performance and scalability of MES systems

MES of the Future deliverables


Unlocking efficiency: a deep dive into MES integration for enhanced biopharmaceutical manufacturing

7 February, 2024
877.78 KB

MES of the future manifesto

26 January, 2022
2.84 MB

More related workstreams

Our workstreams focus on the areas with the greatest impact across the industry. Led by science, our members are problem-solving today’s sustainability issues. By working with the regulatory governance community, they are also creating future-ready outcomes for the industry.

Contact BioPhorum

To find out more about how BioPhorum can help your business, enter your details below and a member of our team will be in touch.

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Investigation Digital Workstreams
Peer to peer practical guidance on remote inspections and audits
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
BioPhorum roundals on sugical gloves
A visionary strategic framework for future patient-centric outbound biopharmaceutical supply chains
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
Lightbulb And Icons On Colourful Background
BioPhorum environmental sustainability roadmap 2022
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing